Theriva Biologics, Inc. TOVX

- Publication in this premier journal after rigorous peer review validates the VIRAGE study and supports the continued evaluation of VCN-01 in the treatment of metastatic pancreatic cancer - - Data are consistent with an immune mediated mechanism of action for VCN-01 that may enhance the antitumor effects of a range of coadministered pancreatic cancer therapies - - The feasibility of administering more frequent repeated VCN-01 doses to potentially improve clinical outcomes in metastatic pancreat

– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients – – Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1 2027 – ROCKVILLE, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing ther